Abeona Therapeutics, Inc. (NASDAQ: ABEO)

This investigation is for anyone who acquired securities in Abeona Therapeutics, Inc. (NASDAQ: ABEO) prior to April 22, 2024.

The Law Offices of Howard G. Smith believes that the Company and certain of its executives violated federal law. Specifically, the Law Offices of Howard G. Smith believes that the Company misled investors regarding its financial condition. More specifically, the Law Offices of Howard G. Smith believes that the Company misled investors by leading investors to believe that the Company would likely receive FDA approval for the Company’s recessive dystrophic epidermolysis bullosa treatment, pz-cel, when the Company knew FDA approval was unlikely considering that the Company knew that it did not meet FDA standards for safe manufacture of the drug.

On April 22, 2024, Abeona disclosed that it had received a Complete Response Letter (“CRL”) from the FDA regarding its recessive dystrophic epidermolysis bullosa treatment, pz-cel, stating that “the FDA noted that certain additional information needed to satisfy Chemistry Manufacturing and Controls (CMC) requirements must be satisfactorily resolved before the application can be approved.” Specifically, the “information needed to satisfy the CMC requests in the CRL pertains to validation requirements for certain manufacturing and release testing methods.” On this news, the price of the Company’s stock dropped precipitously on unusually heavy trading volume.

The Law Offices of Howard G. Smith seeks to recover damages on behalf of class members. If you acquired securities in Abeona Therapeutics, Inc. (NASDAQ: ABEO) prior to April 22, 2024 you may join the lawsuit by submitting your information online, or you may call the Law Offices of Howard G. Smith and speak to Mr. Smith directly to learn how he can protect your rights.